Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hemant Surgical Industries's annualized ROCE % for the quarter that ended in Mar. 2026 was 25.90%.
Hemant Surgical Industries (BOM:543916) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemant Surgical Industries (BOM:543916) has a ROCE % of 25.90% as of Mar. 2026.
Is Hemant Surgical Industries' ROCE % too high?
Hemant Surgical Industries' current ROCE % is 25.90%. The Medical Devices & Instruments industry median ROCE % is 2.30. Hemant Surgical Industries' value of 25.90% is 1028.5% above this industry median. Overall, Hemant Surgical Industries has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hemant Surgical Industries' ROCE % compare to ABT and SYK?
Hemant Surgical Industries' ROCE % of 25.90% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.30. Hemant Surgical Industries' value of 25.90% is 1028.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.30, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemant Surgical Industries's current ROCE % of 25.90% is 1028.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemant Surgical Industries's current ROCE % is 25.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemant Surgical Industries stock overvalued right now?
Based on GuruFocus' analysis, Hemant Surgical Industries (BOM:543916) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹332.62, compared to a current price of ₹380.90 — trading 14.5% above its estimated fair value. The current ROCE % is 25.90% and 1028.5% above the Medical Devices & Instruments industry median of 2.30. Hemant Surgical Industries' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Hemant Surgical Industries (BOM:543916), the current ROCE % is 25.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hemant Surgical Industries (BOM:543916) Overvalued in 2026?
Based on GuruFocus' analysis, Hemant Surgical Industries stock appears to be overvalued.
The current stock price of ₹380.90 is trading 14.5% above its estimated GF Value™ of ₹332.62.
GuruFocus considers Hemant Surgical Industries to be Modestly Overvalued.
Key valuation signals for BOM:543916:
ROCE %: 25.90%
GF Value™: ₹332.62 vs. price of ₹380.90 (14.5% above fair value)
Industry Position: 1028.5% above the Medical Devices & Instruments median
No single metric tells the full story. See the BOM:543916 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hemant Surgical Industries Ltd is engaged in Importing, manufacturing, and marketing quality surgical and Pharmaceutical Products at an economical price. Its product offerings cover a wide spectrum of equipment and disposables required for (i) Renal Care, (ii) Cardiovascular Disease, (iii) Respiratory Disease, (iv) Critical Care and Radiology, and (v) Surgical disposables. Its products include JMS Meditape, JMS Infusion Set, JMS Scalp Vein Set, Ventilators, ECG Machines, and others.
80GF Score
Get the complete analysis for BOM:543916
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543916 has been successfully added to your 
